Investing in weight loss drugs means gaining exposure to one of the fastest-growing segments in pharmaceutical history. J.P. Morgan Global Research forecasts the global market for these medications will reach $200 billion by 2030, driven by drugs that help patients lose 15% to 25% of their body weight in roughly a year. You can invest through individual stocks of drugmakers, through focused ETFs, or by targeting smaller pipeline companies with higher risk and potentially higher reward.
Why This Market Is Growing So Fast
The current generation of weight loss drugs works by mimicking gut hormones that regulate appetite and blood sugar. Novo Nordisk’s semaglutide (sold as Wegovy) and Eli Lilly’s tirzepatide (sold as Zepbound) are the dominant products, and both companies have seen their revenues and stock prices surge as demand consistently outpaces supply. The drugs are also being studied for benefits beyond weight loss, including heart disease, sleep apnea, and liver disease, which could expand their addressable market even further.
A major catalyst is coming from insurance coverage. Medicare has historically not covered weight loss drugs, but that’s changing. Starting in July 2026, a Medicare bridge program will cover Wegovy and Zepbound for eligible beneficiaries enrolled in standalone prescription drug plans or Medicare Advantage plans with drug coverage. Full Medicare Part D access launches in January 2027, and Medicaid coverage may begin as early as May 2026 for participating states. Broader insurance coverage means millions more patients can afford treatment, which directly translates to revenue growth for manufacturers.
The Major Players Right Now
Novo Nordisk and Eli Lilly are the two companies that dominate weight loss drug sales today. Any investor considering this space needs to understand the competitive dynamics between them.
Novo Nordisk makes semaglutide, the active ingredient in both Ozempic (for diabetes) and Wegovy (for weight loss). The company had a first-mover advantage and built enormous brand recognition. However, it faces a significant patent risk: semaglutide’s longest-filed patent expires in March 2026, opening the door to generic competition in the coming years. That timeline is a key factor for anyone evaluating Novo Nordisk as a long-term hold.
Eli Lilly’s tirzepatide targets two gut hormones instead of one, and clinical data has generally shown slightly greater weight loss. Lilly is also developing retatrutide, a triple-hormone drug that produced up to 24.2% body weight reduction at the highest dose in a Phase 2 trial published in the New England Journal of Medicine. Lilly also has an oral version of its weight loss drug in Phase 3 trials, with results expected in 2025. A pill form could be a game-changer for patient adoption, since current treatments require weekly injections. Lilly’s deeper pipeline gives it more shots on goal, which is one reason the stock often trades at a premium valuation.
Smaller Companies With Pipeline Potential
Beyond the two market leaders, several smaller pharmaceutical companies are developing next-generation weight loss drugs. These carry more risk but offer the kind of upside that early-stage biotech investing is known for.
Amgen is developing MariTide, which showed up to 20% average weight loss at 52 weeks in a Phase 2 study for people with obesity, and notably did so without hitting a weight loss plateau. That detail matters because it suggests patients could lose even more weight with longer treatment. In patients with Type 2 diabetes, who typically respond less to these drugs, MariTide still achieved roughly 17% weight loss. MariTide also has a potential dosing advantage: it may require less frequent injections than current options, which could attract patients and insurers alike.
Viking Therapeutics is a much smaller company developing VK2735 in both injectable and oral forms. It’s earlier in clinical development and therefore riskier, but a buyout by a larger pharma company is always a possibility in this space. Multiple companies are racing to develop oral pills that match the efficacy of injections, and whoever cracks that formula could capture significant market share. Science.org reported that several companies are pursuing this “second revolution” in pill form.
How to Get Exposure: Stocks vs. ETFs
The simplest approach is buying shares of Novo Nordisk or Eli Lilly directly. Both are large, profitable companies with diversified drug portfolios beyond weight loss. The tradeoff is that their stock prices already reflect high expectations for future growth, so you’re paying a premium for relative safety.
If you want broader exposure without picking individual winners, several ETFs now focus specifically on the weight loss drug theme. The Roundhill GLP-1 & Weight Loss ETF (ticker: OZEM) is one of the most targeted options. The Amplify Weight Loss Drug & Treatment ETF (THNR) and the Tema Obesity & Cardiometabolic ETF (HRTS) also provide baskets of companies across the weight loss supply chain, including drugmakers, device companies, and firms involved in adjacent treatments. These ETFs spread your risk across multiple companies, so one clinical trial failure or patent loss won’t sink your entire position.
For investors comfortable with more volatility, buying shares in pipeline-stage companies like Viking Therapeutics or Structure Therapeutics offers leveraged upside to positive clinical data. These stocks can double on a good trial readout or drop 50% on a bad one.
Key Risks to Understand
Patent expirations are the most concrete near-term risk. Semaglutide’s patent expires in March 2026, and liraglutide (the older weight loss drug sold as Saxenda) already lost patent protection in late 2024. Generic versions of these drugs could erode Novo Nordisk’s pricing power, though biosimilar development for injectable drugs is slower and more complex than for simple pills. By contrast, some competitors have much longer patent runways: Eli Lilly’s dulaglutide is protected until 2039.
Competition is intensifying quickly. If Amgen’s MariTide or Lilly’s retatrutide deliver superior efficacy or more convenient dosing, current market leaders could lose share. The arrival of effective oral options could reshape the market entirely, since many patients resist weekly injections. Pricing pressure from insurers and government programs is another factor. Medicare coverage will bring volume, but it will also bring negotiation leverage that could compress profit margins over time.
There’s also the broader question of demand durability. These drugs require ongoing use to maintain weight loss, so the patient base is largely recurring. But if side effects emerge with long-term use, or if cheaper alternatives like compounded versions gain traction, growth projections could prove too optimistic.
Building a Position
Most financial professionals suggest sizing your position according to your risk tolerance. A conservative approach might allocate a small percentage of your portfolio to a weight loss ETF, giving you diversified exposure without needing to pick the eventual winner. A more aggressive approach might combine a core holding in Eli Lilly or Novo Nordisk with smaller positions in one or two pipeline companies.
Timing matters less than you might think in a market projected to grow fivefold or more by 2030. What matters more is understanding the catalysts ahead: Medicare coverage rollout in 2026 and 2027, Phase 3 trial readouts for oral formulations, and competitive data from companies like Amgen. Each of these events will move stock prices, and knowing the timeline helps you avoid panic-selling on short-term volatility. The weight loss drug market is still in its early innings, but the stocks already price in significant growth, so your returns will depend on whether reality exceeds or falls short of those expectations.